Feasibility of influenza test‐and‐treat strategy
infections
ADVERSE EVENTS, INFECTIONS
Of all ARI‐participant encounters, 37.4% reported symptom onset < 48 h (Table All 21 positives were treated with an antiviral, including 12 with oseltamivir and 9 with baloxavir; 38% of those treated were <5 years old. Of the 51 symptomatic infections identified through RT‐PCR, 64.7% had symptom onset < 48 h of specimen collection. Of the 32 symptomatic infections identified through RT‐PCR during intervention periods, 19 (59.4%) also were detected <48 h of symptom onset by the rapid molecular test and received immediate antiviral treatment. Of the 6 oseltamivir recipients with follow‐up data, 4 (66%) were fully treatment adherent with no missed doses. Of the 21 participants who received either antiviral, 14 (66.7%) returned for their first follow‐up study visit; only 1 (4.8%) returned for both study visits in the week following treatment. No severe adverse events were identified over the study period.